Although the combination of chemotherapy drugs with targeted mTOR inhibitors seems to be tolerated with low toxicity in ALL treatment, further studies will be necessary to define the most effective pharmacological protocols and drug doses to reduce adverse effects. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.